Wacker Biotech and Eclipsebio Announce Strategic Collaboration to Advance the Development and Production of RNA Therapeutics
The partnership combines AI-driven RNA design with GMP-compliant manufacturing of plasmid DNA, RNA, and LNPs
Advertisement
- Wacker Biotech supplies GMP-compliant plasmid DNA, RNA, and LNPs that are ready for scaling.
- Eclipsebio provides an integrated platform for AI-driven design and sequence-based characterization.
- Together, the companies offer world-class end-to-end development of RNA therapeutics—from the design and optimization of drug candidates to GMP manufacturing and LNP formulation.
Wacker Biotech is a wholly owned subsidiary of Wacker Chemie AG and a contract developer and manufacturer of biopharmaceutical active ingredients (CDMO). The company today announced a strategic collaboration with Eclipse Bioinnovations, Inc. (Eclipsebio). Eclipsebio specializes in sequence-based analytics and AI-driven design for RNA therapeutics. The partnership will further strengthen the companies’ offerings for developers of RNA therapeutics.
This collaboration combines Eclipsebio’s integrated platform for AI-optimized RNA design and sequence-based validation with Wacker Biotech’s large-scale, GMP-compliant manufacturing of nucleic acid-based therapies. Eclipsebio designs RNA with both manufacturability and efficacy in mind, focusing on high yield, integrity, purity, stability, and protein expression. As a CDMO, WACKER covers the entire value chain of RNA-based therapeutic approaches, from plasmid DNA through in vitro transcription (IVT) for GMP-compliant RNA to its formulation in lipid nanoparticles (LNPs) that meet regulatory standards. Together, the companies will enhance opportunities for drug developers to produce clinically ready RNA.
“We are very pleased to expand our collaboration with WACKER,” said Dr. Peter Chu, co-founder and CEO of Eclipsebio. “This partnership enables us to offer our partners innovative access and better support at every stage of drug development—whether they need initial mRNA designs that deliver high yields or are already ready for IVT scaling.”
“We’ve been working together for some time now, and Eclipsebio’s new RNA design services are an important offering for early-stage customers whom we support with our newly launched contract research services (CRS),” said Hagen Richter, Head of Global Innovation BioPharma at WACKER. “This collaboration leverages our complementary strengths to offer customers high-performance, clinically ready RNA.”
About Eclipsebio
Eclipsebio is a privately held biotechnology company headquartered in San Diego that combines AI-powered sequence design, rapid prototyping, and sequence-based analytics to support the development of RNA therapeutics. With extensive experience in supporting basic research from the early stages through to preclinical development of therapeutics, Eclipsebio offers unparalleled support in gaining deep insights into RNA and therapeutic biology. The company offers its solutions as end-to-end partnerships for the biopharma industry and as project-based services for academic institutions.
About Wacker Biotech
Wacker Biotech is a full-service contract manufacturer of recombinant proteins based on microbial systems, live microbial products (LMPs), plasmid DNA (pDNA), and ribonucleic acid (RNA) for therapeutics and vaccines. Wacker Biotech’s portfolio ranges from strain and process development through analytical testing to GMP-compliant production for clinical and commercial applications. Wacker Biotech operates three GMP-compliant production facilities—all of which have been inspected by the FDA and the EMA—at its sites in Jena and Halle, Germany, as well as in Amsterdam, the Netherlands. In addition, Wacker Biotech operates a GMP-compliant facility in San Diego (Wacker Biotech US Inc.) that specializes in the production of pDNA, a crucial starting point for RNA therapeutics. These production sites are complemented by a central biotechnology research and development center in Munich, which offers contract research services. Wacker Biotech GmbH, Wacker Biotech B.V., and Wacker Biotech US Inc. are wholly owned subsidiaries of Munich-based Wacker Chemie AG.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
